These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21984146)

  • 1. [GVHD with GVL separation strategy in allogeneic hematopoietic stem cell transplantation].
    Huang H; Liu LZ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 40(5):461-6. PubMed ID: 21984146
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia.
    Parmar S; Fernandez-Vina M; de Lima M
    Curr Opin Hematol; 2011 Mar; 18(2):98-104. PubMed ID: 21245756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [GVHD and GVL].
    Teshima T
    Rinsho Ketsueki; 2009 Oct; 50(10):1407-19. PubMed ID: 19915349
    [No Abstract]   [Full Text] [Related]  

  • 7. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.
    van der Straaten HM; Fijnheer R; Nieuwenhuis HK; van de Winkel JG; Verdonck LF
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):206-12. PubMed ID: 15744239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
    Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia effect of allogeneic stem cell transplantation; a Japanese single center study.
    Ishiyama K; Takami A; Shiobara S; Koizumi S; Nakao S;
    Haematologica; 2004 Jul; 89(7):887-9. PubMed ID: 15257954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
    Tanaka J
    Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the T-cell receptor V beta gene repertoire after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Li YQ; Yang D; Zhang Y; Yang LJ; Chen SH; Sun J; Liu XL; Zhou SY
    Chin Med J (Engl); 2004 Mar; 117(3):413-8. PubMed ID: 15043783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of GVHD without losing GVL effect: windows of opportunity.
    Zhang P; Chen BJ; Chao NJ
    Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].
    Ichinohe T; Ishikawa T
    Nihon Rinsho; 2003 Sep; 61(9):1573-8. PubMed ID: 14515726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.